@article{HaferkampHesbacherWeyandtetal.2014,
  author    = {Haferkamp, Sebastian and Hesbacher, Sonja and Weyandt, Gerhard and Vetter-Kauczok, Claudia S. and Becker, J{\"u}rgen C. and Motschenbacher, Stephanie and Wobser, Marion and Maier, Melissa and Schmid, Corinna P. and Houben, Roland},
  title     = {p53 regulation by TRP2 is not pervasive in melanoma},
  doi       = {10.1371/journal.pone.0087440},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-111396},
  year      = {2014},
  abstract  = {p53 is a central tumor suppressor protein and its inhibition is believed to be a prerequisite for cancer development. In approximately 50\% of all malignancies this is achieved by inactivating mutations in the p53 gene. However, in several cancer entities, including melanoma, p53 mutations are rare. It has been recently proposed that tyrosinase related protein 2 (TRP2), a protein involved in melanin synthesis, may act as suppressor of the p53 pathway in melanoma. To scrutinize this notion we analyzed p53 and TRP2 expression by immunohistochemistry in 172 melanoma tissues and did not find any correlation. Furthermore, we applied three different TRP2 shRNAs to five melanoma cell lines and could not observe a target specific effect of the TRP2 knockdown on either p53 expression nor p53 reporter gene activity. Likewise, ectopic expression of TRP2 in a TRP2 negative melanoma cell line had no impact on p53 expression. In conclusion our data suggest that p53 repression critically controlled by TRP2 is not a general event in melanoma.},
  language  = {en}
}
@article{BaurMatheGesierichetal.2017,
  author    = {Baur, Johannes and Mathe, Katrin and Gesierich, Anja and Weyandt, Gerhard and Wiegering, Armin and Germer, Christoph-Thomas and Gasser, Martin and Pelz, J{\"o}rg O. W.},
  title     = {Morbidity and oncologic outcome after saphenous vein-sparing inguinal lymphadenectomy in melanoma patients},
  series = {World Journal of Surgical Oncology},
  volume    = {15},
  journal   = {World Journal of Surgical Oncology},
  number    = {99},
  doi       = {10.1186/s12957-017-1164-x},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-157687},
  year      = {2017},
  abstract  = {Background: Inguinal lymph node dissection (LND) is a surgical procedure with a high morbidity rate. Variations in surgical procedure, such as sparing of the saphenous vein, have been proposed to reduce surgical morbidity. While sparing of the saphenous vein has shown promising results in earlier studies, data for this procedure in melanoma patients are rare. In this retrospective study, we report 10-year findings on the effects of saphenous vein-sparing LND on surgical morbidity and oncologic outcomes in melanoma patients. Methods: A retrospective analysis of melanoma patients receiving inguinal LND in our facility between 2003 and 2013 was performed. Patients were divided into two groups: the saphenous vein resection group and the vein sparing group. Surgical morbidity, including wound infection, lymphatic fistula, severe bleeding, neurological complications, and chronic lymphedema, as well as regional recurrence-free survival were investigated. Results: A total of 106 patients were included in this study; of these, the saphenous vein was spared in 41 patients (38.7\%). The rate of lymphatic fistula was 51.6 vs. 48.8\%, wound infection occurred in 31.3 vs. 24.4\%, and patients suffered from chronic lymphedema in 30.0 vs. 26.5\% in V. saphena magna resection vs. sparing group. Differences observed, however, were not significant. No difference in regional recurrence-free survival between the two study groups was detected. Conclusions: The results of our retrospective analysis could not confirm the promising results reported in earlier studies. Thus, sparing of the saphenous vein appears to be optional.},
  language  = {en}
}